Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval

On May 2, 2013, AVEO Oncology is set to face the FDA's Oncologic Drugs Advisory Committee for a review of the company's New Drug Application for tivozanib, the proposed indication for treatment of patients with advanced renal cell carcinoma.

http://seekingalpha.com/article/1365621-aveo-s-inflection-point-tivozanib-likely-to-receive-positive-advisory-vote-fda-approval?source=feed